Glenmark Launches Generic Version of Pfizer's Inlyta for Kidney Cancer in US
Glenmark Pharmaceuticals Inc, USA, has launched Axitinib Tablets in 1 mg and 5 mg strengths, a generic version of Pfizer's Inlyta tablets used to treat advanced renal cell carcinoma, a type of kidney cancer. The company highlighted its commitment to expanding access to affordable medicines in the US. According to IQVIA data, Inlyta's annual sales in the US were approximately USD 538.4 million for the 12 months ending September 2026, underscoring the market potential for Glenmark's generic product.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (58/100). Lens Score 37/100.
Outlets measured: economictimes, businessstandard, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–68/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 16 Nov, 06:30 am. Other outlets followed.
